异常循环的类固醇可以在缺血性心脏病中提炼心力衰竭进展的风险
Yangkai Fan1,2, Fengjuan Li1,2, Xin Tan1,2
1Beijing Collaborative Innovation Centre for Cardiovascular Disorders, The Key Laboratory of Remodeling-Related Cardiovascular Disease, Ministry of Education, Beijing Anzhen Hospital, Capital Medical University, Beijing, China.
European journal of clinical investigation
|January 12, 2024
概括
类固醇激素失衡与缺血性心脏病 (IHD) 患者的心力衰竭 (HF) 有关. 一个新的类固醇心力衰竭评分 (SHFS) 识别了针对性干预的高风险个体.
科学领域:
- 心脏病学 心脏病学
- 内分泌学 在内分泌学.
- 生物标志物发现发现
背景情况:
- 缺血性心脏病 (IHD) 经常进展到心力衰竭 (HF),尽管存在治疗方法.
- 类固醇激素代谢障碍越来越多地被认为是不利的心血管表型的潜在贡献者,包括HF.
研究的目的:
- 调查特定类固醇特征与患有缺血性心脏病患者心力衰竭的风险之间的关联.
- 开发和验证基于类固醇特征的预测得分,用于发生心力衰竭.
主要方法:
- 在BIOMS-IHD注册表中的2023名患者中,使用液体染色学-并联质谱测量量量化了18种类固醇.
- 利用IHD患者的回顾性发现和多中心验证队列,随访时间中位数为4年.
- 评估发生的心力衰竭事件作为主要结果.
主要成果:
- 基于类固醇的标记反映了炎症,冠状动脉微血管功能障碍和左心室缩与随后的HF事件有关.
- 较高的类固醇心力衰竭评分 (SHFS > 1) 与较低的评分 (SHFS ≤ 1) 相比,在两个队列中显著增加了发生心力衰竭的风险.
- SHFS提高了预后准确度,超出了传统的临床变量,并在IHD患者中表现出最大的效果,其B型尿素水平较低.
结论:
- 一个简单的,基于类固醇的策略有效地识别了心脏衰竭风险较高的IHD患者.
- 这种风险分层可能会为高风险个体提供更密集的随访和个性化治疗策略.
相关概念视频
01:17Ischemic Heart Disease: Overview
1.3K
Ischemic heart disease occurs when the heart's blood supply dwindles, causing an ominous lack of oxygen and nutrients. This deficiency, stemming from reduced or obstructed blood flow, spells danger, leading to heart muscle damage and dysfunction.
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and...
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and...
1.3K
01:22Heart Failure Drugs: Diuretics
384
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
384
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
432
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
432
01:17Pathophysiology of Heart Failure
1.6K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.6K
01:26Imbalances in Cardiac Output
1.4K
The heart's primary function is to pump blood throughout the body, maintaining a balance between blood sent out (cardiac output) and blood returning (venous return). If this balance is disrupted, it can result in congestive heart failure (CHF), a severe condition where the heart becomes an inefficient pump, leading to inadequate blood circulation.
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send...
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send...
1.4K
01:22Heart Failure Drugs: β-Blockers
341
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
341